Showing 91-100 of 9253 results for "".
- Cetaphil Brand Revamps RestoraDerm Product Linehttps://practicaldermatology.com/news/20141117-cetaphil_brand_revamps_restoraderm_product_line/2459061/Galderma Laboratories, LP unveiled a new and improved look for their Cetaphil RestoraDerm product line. The new look brings eczema to the forefront of the packaging featuring their new names, Cetaphil RestoraDerm Eczema Calming Body Wash and Cetaphil RestoraDerm Eczema Calming M
- Sente, Inc. Awarded European Patent for Active Ingredient in Proprietary Dermal Repair Creamhttps://practicaldermatology.com/news/20140619-sente_inc_awarded_european_patent_for_active_ingredient_in_proprietary_dermal_repair_cream/2459199/Sente has been granted the European Patent for use of a low molecular weight heparan sulfate (HS) for cosmetic products. HS is the most biologically active glycoprotein that is present in all layers of human skin and is the scientific base to Sente Inc's proprietary Dermal Repair Cream. M
- Residents Provided with Online Education by ASDShttps://practicaldermatology.com/news/20140416-residents_provided_with_online_education_by_asds/2459270/Kyle M. Coleman, MD, has developed a dermatologic surgery educational series as part of the ASDS Future Leaders Network. The "Better Surgical Education" video series, focusing on dermatologic surgery topics and procedures, will provide additional education opportunities for residency programs.
- SGR Patch: AADA Disappointed By Congressional Actionhttps://practicaldermatology.com/news/20140401-sgr_patch_aada_disappointed_by_congressional_action/2459285/Statement from Brett M. Coldiron, MD, FAAD President, American Academy of Dermatology Association: The U.S. House of Representatives and Senate have averted a 24 percent cut in Medicare physician payments by agreeing to a one-year short-term measure (HR 4302) to maintain current Medicare payment r
- Alphaeon Acquires US License To Teoxane Laboratories' Dermal Fillers And Cosmeceutical Productshttps://practicaldermatology.com/news/20130802-alphaeon_acquires_us_license_to_teoxane_laboratories_dermal_fillers_and_cosmeceutical_products/2459484/Alphaeon Corporation, a wholly-owned subsidiary of Strathspey Crown Holdings, LLC, has acquired an exclusive US license for the full line of products from Teoxane Laboratories. Containing 100 percent non-animal origin, resorbable hyaluronic acid, Teoxane's dermal fillers are currently available in m
- New Jersey Passes Law Prohibiting Indoor Tanning for Those Under 17https://practicaldermatology.com/news/20130402-new_jersey_passes_law_prohibiting_indoor_tanning_for_those_under_17/2459575/The state of New Jersey recently passed a law that bans minors under the age of 17 years old from using indoor tanning devices. The law passed both the New Jersey House and Senate in February and was signed into law by Gov. Christopher Christie on April 1, 2013. Dirk M. Elston, MD, FAAD, President o
- Report: Estimated 4.7 Million Americans Diagnosed With NMSC Annuallyhttps://practicaldermatology.com/news/report-estimated-47-million-americans-diagnosed-with-nmsc-annually/2488474/A new analysis from SkinCure Oncology estimates that 4.7 million Americans are diagnosed with nonmelanoma skin cancer (NMSC) each, approximately 42% higher than a commonly cited estimate based on 2012 data.
- Meta-Analysis: IBD Events Are Rare With IL-17 Inhibitors in HShttps://practicaldermatology.com/news/meta-analysis-finds-rare-ibd-events-with-il-17-inhibitors-in-hs/2488443/Interleukin (IL)-17 inhibitors were not associated with a statistically significant increase in inflammatory bowel disease (IBD) risk among patients with hidradenitis suppurativa (HS) in a systematic review and meta-analysis published online in JAMA Dermatology. IBD Events Remain
- Ultra-Processed Foods May Influence Pediatric Acne Through mTORC1 Signaling: Studyhttps://practicaldermatology.com/news/ultra-processed-foods-may-influence-pediatric-acne-through-mtorc1-signaling-study/2488415/Ultra-processed foods may contribute to pediatric acne through metabolic, inflammatory, and microbiome-related pathways, according to a comprehensive review published in the International Journal of Molecular Sciences. Researchers examined current evidence connecting ultra-processed foods
- Omalizumab Shows Median 3.1-Year Drug Survival in Chronic Urticariahttps://practicaldermatology.com/news/omalizumab-shows-median-31-year-drug-survival-in-chronic-urticaria/2488414/Omalizumab demonstrated a median drug survival of more than 3 years among patients with chronic urticaria (CU), with successful disease control rather than adverse events emerging as a common reason for treatment discontinuation, according to a systematic review an